Table 2.

OCS dose reduction from benralizumab treatment initiation to 96 weeks of treatment

Variable	Number (%) of patients with OCS reduction at 48 weeks (N = 34)	Number (%) of patients with OCS reduction at 96 weeks (N = 30)
OCS interruption	18 (52.9)	18 (60.0)
Any OCS reduction (including interruption)	21 (61.8)	20 (66.7)
≥ 90% OCS dose reduction	18 (52.9)	18 (60.0)
≥ 75% OCS dose reduction	18 (52.9)	18 (60.0)
≥ 25% OCS dose reduction	20 (58.8)	19 (63.3)
No OCS reduction	13 (38.2)	10 (33.3)

OCS dosage is expressed as daily mg (prednisone equivalent). Evaluable patients for secondary analyses at 48 and 96 weeks with OCS dose available were considered (N = 34 and N = 30, respectively). Data are expressed as N (%)